Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18127944 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL570471 | 0.83 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6887811 | 0.80 | SMN1; SMN2 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3487721 | 0.80 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12831173 | 0.78 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22423696 | 0.78 | ALDH1A1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5833788 | 0.78 | TSHR (0.57) | TSHRKMT2AMEN1TDP1RAB9A | |
| SCHEMBL22407682 | 0.77 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6068040 | 0.77 | TSHR (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4843311 | 0.77 | ALDH1A1 (0.59) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101912-B2 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XENOPORT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XIANG JIA-NING (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004052841-A1 | CARBIDOPA PRODRUGS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | PDE3A, ADORA2A, CDA | CA12 663/4885CA1 433/4885CA2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.